局所薬物デリバリーの世界市場予測（～2024年）...市場調査レポートについてご紹介

1 Introduction (Page No. – 20)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders
2 Research Methodology (Page No. – 23)
2.1 Research Data
2.1.1 Secondary Data
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Data
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Key Industry Insights
2.2 Market Size Estimation
2.2.1 Bottom-Up Approach
2.2.2 Top-Down Approach
2.2.3 Growth Forecast
2.3 Market Data Validation and Triangulation
2.4 Assumptions for the Study
3 Executive Summary (Page No. – 32)
4 Premium Insights (Page No. – 35)
4.1 Market Overview
4.2 North America: Market, By Product, 2018
4.3 Europe: Market, By Facility of Use, 2018
4.4 Market: Geographic Snapshot
5 Market Overview (Page No. – 39)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Prevalence of Skin Diseases
5.2.1.2 Rising Prevalence of Eye Diseases
5.2.1.3 High Incidence of Burn Injuries
5.2.1.4 Growing Prevalence of Diabetes
5.2.2 Restraints
5.2.2.1 Preference for Alternative Modes of Drug Delivery
5.2.3 Opportunities
5.2.3.1 Delivery of Biologics Through the Transdermal Route
5.2.3.2 Self-Administration and Home Care
5.2.4 Challenges
5.2.4.1 Technical Barriers Related to Skin Irritation and Permeability
5.2.4.2 Drug Failures and Product Recalls
6 Topical Drug Delivery Market, By Product (Page No. – 44)
6.1 Introduction
6.2 Semi-Solid Formulations
6.2.1 Creams
6.2.1.1 Ease of Spreadability and Washability to Drive This Market Segment
6.2.2 Ointments
6.2.2.1 Ointments are Widely Used in Analgesic Indications
6.2.3 Lotions
6.2.3.1 Easy Administration of Lotions to Drive Their Demand Among End Users
6.2.4 Gels
6.2.4.1 Faster Drug Release and Greater Patient Acceptability to Drive the Market for Topical Gels
6.2.5 Pastes
6.2.5.1 Topical Pastes are Widely Used for the Treatment and Prevention of Skin Irritation
6.3 Liquid Formulations
6.3.1 Suspensions
6.3.1.1 Higher Rate of Bioavailability and Controlled Onset of Action to Support the Growth of the Topical Suspensions Market
6.3.2 Solutions
6.3.2.1 Topical Solutions Comprise Soluble Chemicals That are Dissolved in Various Solvents
6.4 Solid Formulations
6.4.1 Powders
6.4.1.1 Powders have A Very Fine Particle Size That Covers A Large Surface Area Per Unit Weight
6.4.2 Suppositories
6.4.2.1 Suppositories Require A Suitable Base That Ensures the Compatibility and Stability of the Drug
6.5 Transdermal Products
6.5.1 Transdermal Patches
6.5.1.1 Transdermal Patches to Account for the Largest Share of the Transdermal Drug Delivery Market in 2019
6.5.2 Transdermal Semi-Solids
6.5.2.1 Transdermal Semi-Solids Segment to Witness Negative Growth During the Forecast Period
7 Topical Drug Delivery Market, By Route of Administration (Page No. – 65)
7.1 Introduction
7.2 Dermal Drug Delivery
7.2.1 Dermal Drug Delivery is the Largest Segment in This Market Due to Advantages Such as Ease of Use and Increased Patient Compliance
7.3 Ophthalmic Drug Delivery
7.3.1 Increasing Use of Mobile Devices is Likely to Impact Vision, Which is A Key Factor Supporting Market Growth
7.4 Rectal Drug Delivery
7.4.1 Poor Absorption of Drugs Through the Rectal Route—A Key Disadvantage Associated With This Market Segment
7.5 Vaginal Drug Delivery
7.5.1 High Permeability of Vaginal Tissues, the Scope of Self-Administration, and Ease of Manufacturing are Expected to Boost the Growth of the Vaginal Drug Delivery Market Segment
7.6 Nasal Drug Delivery
7.6.1 Absence of Drug Degradation, High Efficacy of Nasally Administered Drugs, and Growing Preference for Self-Administration to Drive Market Growth
8 Topical Drug Delivery Market, By Facility of Use (Page No. – 72)
8.1 Introduction
8.2 Home Care Settings
8.2.1 Home Care Settings Accounted for the Largest Share in 2018
8.3 Hospitals and Clinics
8.3.1 Rising Incidence of Surgical Site Infections to Drive This Segment
8.4 Burn Centers
8.4.1 High Incidence of Burn Injuries Across the Globe to Support the Market Growth
8.5 Other Facilities
9 Topical Drug Delivery Market, By Region (Page No. – 78)
9.1 Introduction
9.2 North America
9.2.1 US
9.2.1.1 Rising Prevalence of Skin Diseases and the Approval and Launch of Innovative Topical Formulations—Key Factors Driving Market Growth
9.2.2 Canada
9.2.2.1 Rising Prevalence of Skin Diseases and Funding for the Development of Topical Drugs to Drive Market Growth
9.3 Europe
9.3.1 Germany
9.3.1.1 Growing Focus of Pharmaceutical Companies on the Development of Topical Products to Drive Market Growth
9.3.2 UK
9.3.2.1 Rising Prevalence of Skin Diseases & Chronic Conditions to Drive Market Growth
9.3.3 France
9.3.3.1 Rising Prevalence of Skin Diseases and Development of Topical Drugs By Local Players to Support Market Growth
9.3.4 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.1.1 Increasing Number of Product Approvals and Growing Focus of Local Players on the R&D of Topical Formulations to Support Market Growth
9.4.2 China
9.4.2.1 Growing Focus of Major Players in China on the Development of Topical Drugs to Drive Market Growth
9.4.3 India
9.4.3.1 Rising Awareness Among Healthcare Providers & Patients and Increasing Focus on Noninvasive Methods of Drug Delivery to Drive Market Growth
9.4.4 Rest of Asia Pacific
9.5 Rest of the World
10 Competitive Landscape (Page No. – 145)
10.1 Overview
10.2 Market Share Analysis
10.2.1 Johnson & Johnson
10.2.2 Nestlé Sa (Galderma)
10.2.3 Novartis
10.3 Competitive Scenario
10.3.1 Product Launches
10.3.2 Expansions
10.3.3 Agreements and Collaborations
10.3.4 Acquisitions
10.4 Competitive Leadership Mapping (Overall Market) (2018)
10.4.1 Visionary Leaders
10.4.2 Innovators
10.4.3 Dynamic Differentiators
10.4.4 Emerging Companies
11 Company Profiles (Page No. – 150)
(Business Overview, Products Offered, Recent Developments, MnM View
11.1 Glaxosmithkline
11.2 Janssen Global Services (A Subsidiary of Johnson & Johnson)
11.3 Bausch Health Companies
11.4 Merck & Co.
11.5 Bayer AG
11.6 Hisamitsu Pharmaceutical
11.7 Nestlé Sa
11.8 Novartis AG
11.9 Glenmark Pharmaceuticals
11.10 Cipla
11.11 Crescita Therapeutics Inc.
11.12 Mylan N.V.
*Business Overview, Products Offered, Recent Developments, MnM View Might Not Be Captured in Case of Unlisted Companies.
12 Appendix (Page No. – 182)
12.1 Discussion Guide
12.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
12.3 Related Reports
12.4 Author Details